Tyrosine Kinase Inhibitors and Interferon‐α Increase Tunneling Nanotube (TNT) Formation and Cell Adhesion in Chronic Myeloid Leukemia (CML) Cell Lines

FASEB Journal - United States
doi 10.1096/fj.201802061rr
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Single-Nucleotide Polymorphisms of ABCG2 Increase the Efficacy of Tyrosine Kinase Inhibitors in the K562 Chronic Myeloid Leukemia Cell Line

Pharmacogenetics and Genomics
Molecular MedicineGeneticsMolecular Biology
2014English

Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

Turkish Journal of Haematology
Hematology
2019English

Complications of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia - Chronic Phase

Revista de Chimie
SurfacesMaterials ScienceEngineeringMaterials ChemistryFilmsCoatingsChemistry
2019English

Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Future Perspectives of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia

Chemotherapy: Open Access
2017English

Preventing and Managing Cardiovascular Toxicities of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Cancer therapy & Oncology International Journal
2018English

Switches of Tyrosine-Kinase Inhibitors in Chronic Phase of Chronic Myeloid Leukemia in Real Life

American Journal of Hematology
Hematology
2018English

Comparative Pharmacology of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

International Journal of Clinical Pharmacology & Pharmacotherapy
2018English

Current Status of ABL Tyrosine Kinase Inhibitors Stop Studies for Chronic Myeloid Leukemia

Stem Cell Investigation
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy